Siyuan Wang, Zhen‐Zhen Yan, Xia Yang, Shimin An, Kuo Zhang, Yu Qi, Jilin Zheng, Yan‐Xiao Ji, Pi‐Xiao Wang, Chun Fang, Xue‐Yong Zhu, Li‐Jun Shen, Feng‐Juan Yan, Rong Bao, Song Tian, Zhi‐Gang She, Yi‐Da Tang – 27 October 2017 – Nonalcoholic fatty liver disease (NAFLD) is a prevalent and complex disease that confers a high risk of severe liver disorders. Despite such public and clinical health importance, very few effective therapies are currently available for NAFLD.

Peter L.M. Jansen – 27 October 2017

26 October 2017

26 October 2017

Vera C. Mazurak, Puneeta Tandon, Aldo J. Montano‐Loza – 26 October 2017 – Cirrhosis is the most common indication for liver transplantation (LT) worldwide. Malnutrition is present in at least two‐thirds of patients with cirrhosis awaiting LT. It negatively impacts survival, quality of life, and the ability to respond to stressors, such as infection and surgery. Muscle wasting or sarcopenia is the most objective feature of chronic protein malnutrition in cirrhosis, and this condition is associated with increased morbidity and mortality before and after LT.

Masaaki Mino, Keishi Kanno, Kousuke Okimoto, Akiko Sugiyama, Nobusuke Kishikawa, Tomoki Kobayashi, Junya Ono, Kenji Izuhara, Tsuyoshi Kobayashi, Toshikazu Ohigashi, Hideki Ohdan, Susumu Tazuma – 25 October 2017 – Periostin, a secreted matricellular protein, has been reported to induce epithelial‐mesenchymal transition (EMT), which increases motility and invasiveness in various epithelial cancer cells.

Federico Piñero, Marcelo Silva – 25 October 2017

This newly added session is designed to complement the highly-regarded, Hepatitis and Clinical Hepatology Debriefs, and will review key highlights from the meeting.Michael W. Fried Kymberly Watt

This session will provide a summary of the clinical highlights from The Liver Meeting®.Michael W. Fried Kris V. Kowdley

As HCV therapies now achieve high rates of SVR across a broad spectrum of individuals in patient care, there is a need to consider those HCV-infected persons who are not or may have difficulty accessing care or engaging in HCV therapy. Additionally, aspects related to prevention of reinfection are relevant in these difficult to reach populations.